Key opinion leaders discuss how bispecifics are administered at their institutions.
Modakafusp Alfa Exhibits Antitumor Activity, Immune Activation in Myeloma
Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Elotuzumab Plus PVd Displays Efficacy in Relapsed/Refractory Multiple Myeloma
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma
Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.
Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies
A cancer care team contemplated the methods and reasoning for handling a complex case of heavily pretreated relapsed or refractory multiple myeloma.
